Tapewire

NYSE · USD

NSRX

Nasus Pharma Ltd

Export transactions ↓
Tapewire entity
7254
SEC CIK
0002029039
Parsed reports
15

Last 12 months

Inside the activity.

3 purchase rows · 0 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202500
Dec 202500
Jan 202600
Feb 202600
Mar 202610
Apr 202610
May 202600
Jun 202610
Jul 202600
Aug 202600
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
June 17, 2026 Filed Jun 22, 2026 11:12 UTC
Teleman Dan BenjaminDirector · Chief Executive Officer
PurchaseOrdinary Shares 6,550 $3.10 $20,305.00
Disclosure

SEC source: 0001493152-26-029484 · ownership.xml · nonDerivative · entry 1

Teleman Dan Benjamin · CIK 0002122500 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 163,541

F1 · balance_after: Consists of: (i) 30,696 ordinary shares, no par value per share ("Ordinary Shares"), and (ii) 132,845 Ordinary Shares issuable upon exercise of outstanding share options that are exercisable within 60 days.

Read SEC document
April 22, 2026 Filed Apr 23, 2026 01:44 UTC
Teleman Dan BenjaminDirector · Chief Executive Officer
PurchaseOrdinary Shares 2,900 $3.76 $10,904.00
Disclosure

SEC source: 0001493152-26-018607 · ownership.xml · nonDerivative · entry 1

Teleman Dan Benjamin · CIK 0002122500 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 156,991

F1 · balance_after: Consists of: (i) 24,146 ordinary shares, no par value per share ("Ordinary Shares"), and (ii) 132,845 Ordinary Shares issuable upon exercise of outstanding share options that are exercisable within 60 days.

Read SEC document
March 31, 2026 Filed Apr 1, 2026 11:31 UTC
Teleman Dan BenjaminDirector · Chief Executive Officer
PurchaseOrdinary Shares 15,000 $2.04 $30,600.00
Disclosure

SEC source: 0001493152-26-014503 · ownership.xml · nonDerivative · entry 1

Teleman Dan Benjamin · CIK 0002122500 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,246

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.